Thursday, October 19, 2023
Walgreens and the Cardiovascular Research Foundation (CRF) have announced a strategic partnership to advance the PREVUE-VALVE study, an innovative population-based clinical trial. This groundbreaking study aims to assess the prevalence of valvular heart disease (VHD) among older Americans and contribute to the development of new diagnostic and treatment solutions. Walgreens, with its extensive national reach, strong community ties, and expertise in data-driven clinical trials, will play a pivotal role in identifying and engaging potential study participants.
The aging U.S. population has seen a significant rise in the incidence and prevalence of valvular heart disease. Unfortunately, many individuals with VHD do not receive timely treatment due to various barriers. Walgreens will provide patient recruitment services to support this study, which is focused on defining the prevalence of VHD among older Americans and ensuring equitable access and enrollment. To enhance participant convenience and engagement, all study procedures will be conducted in the comfort of their homes.
By leveraging insights from longitudinal pharmacy data, social determinants of health, and proprietary automated recruitment selection software, Walgreens aims to reach eligible patients for enrollment at the right time, delivering the appropriate message and facilitating their seamless participation.
Traditionally, estimates of VHD prevalence in the United States have been drawn from relatively homogeneous populations with limited diversity, particularly regarding race and ethnicity. Furthermore, the older population, where VHD is more common, has been underrepresented in clinical trials.
Source: businesswire.com
